Abstract:Cellular senescence describes an irreversible growth arrest characterized by distinct morphology, gene expression pattern, and secretory phenotype. The final or intermediate stages of senescence can be reached by different genetic mechanisms and in answer to different external and internal stresses. It has been maintained in the literature but never proven by clearcut experiments that the induction of senescence serves the evolutionary purpose of protecting the individual from development and growth of cancers. This hypothesis was recently scrutinized by new experiments and found to be partly true, but part of the gene activities now known to happen in senescence are also needed for cancer growth, leading to the view that senescence is a double-edged sword in cancer development. In current cancer therapy, cellular senescence is, on the one hand, intended to occur in tumor cells, as thereby the therapeutic outcome is improved, but might, on the other hand, also be induced unintentionally in non-tumor cells, causing inflammation, secondary tumors, and cancer relapse. Importantly, organismic aging leads to accumulation of senescent cells in tissues and organs of aged individuals. Senescent cells can occur transiently, e.g., during embryogenesis or during wound healing, with beneficial effects on tissue homeostasis and regeneration or accumulate chronically in tissues, which detrimentally affects the microenvironment by de- or transdifferentiation of senescent cells and their neighboring stromal cells, loss of tissue specific functionality, and induction of the senescence-associated secretory phenotype, an increased secretory profile consisting of pro-inflammatory and tissue remodeling factors. These factors shape their surroundings toward a pro-carcinogenic microenvironment, which fuels the development of aging-associated cancers together with the accumulation of mutations over time. We are presenting an overview of well-documented stress situations and signals, which induce senescence. Among them, oncogene-induced senescence and stress-induced premature senescence are prominent. New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors.

Senescence-associated reprogramming promotes cancer stemness

Senescence Promotes the Recovery of Stemness among Cancer Cells via Reprograming

Chemotherapy-Induced Cellular Senescence Promotes Stemness of B-Cell Non-Hodgkin's Lymphoma Via CCL21/CCR7/NF-Κb Signaling Activation

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression

Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling

Tumor cell senescence response produces aggressive variants

Senescence and cancer — role and therapeutic opportunities

Is Senescence Reversible?

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Senescent Cells in Growing Tumors: Population Dynamics and Cancer Stem Cells

Senescent T cells: a potential biomarker and target for cancer therapy

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma

Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications

The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy

Exploiting senescence for the treatment of cancer

The Potent and Paradoxical Biology of Cellular Senescence in Cancer

Control of the Senescence-Associated Secretory Phenotype by NF-κB Promotes Senescence and Enhances Chemosensitivity.

Senescent Cells: A New Achilles’ Heel to Exploit for Cancer Medicine?

Mesenchymal Stromal Cell Senescence Induced by -Mutant Hematopoietic Cells is a Targetable Mechanism Driving Clonal Hematopoiesis and Initiation of Hematologic Malignancy